Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Minireview

Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis

Antonio Cassone, Jack D. Sobel
A. T. Maurelli, Editor
Antonio Cassone
aPolo d'innovazione della genomica, genetica e biologia, Università di Perugia, Perugia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack D. Sobel
bDetroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. T. Maurelli
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.01544-15
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Vulvovaginal candidiasis (VVC) is a high-incidence disease seriously affecting the quality of life of women worldwide, particularly in its chronic, recurrent forms (RVVC), and with no definitive cure or preventive measure. Experimental studies in currently used rat and mouse models of vaginal candidiasis have generated a large mass of data on pathogenicity determinants and inflammation and immune responses of potential importance for the control of human pathology. However, reflection is necessary about the relevance of these rodent models to RVVC. Here we examine the chemical, biochemical, and biological factors that determine or contrast the forms of the disease in rodent models and in women and highlight the differences between them. We also appeal for approaches to improve or replace the current models in order to enhance their relevance to human infection.

INTRODUCTION

Among human diseases caused by Candida albicans, vulvovaginal candidiasis (VVC), especially in its chronic and recurrent forms (RVVC), is by far the most frequent. Recent epidemiological investigations have given a global estimate of RVVC incidence approaching 2%, which compares with the highest incidence of any single infectious disease on our planet (1). Although not a lethal disease, the quality of life of young women in their most socially and economically productive period can be truly devastated. Past and recent reviews highlight the dominant signs and symptoms of RVVC that make this chronic disease so devastating (2, 3). With the above premise, the magnitude of the efforts made by a number of investigators to identify disease mechanisms and host inflammatory and immune responses in vaginal candidiasis by adopting animal models of the disease is admirable. In some cases, the data obtained by the use of the models described above directed the investigators toward the choice of vaccine candidates or, more recently, toward devising novel therapeutic options based on the control of pathogenic vaginal inflammation (4–8). Overall, research has now progressed to promising future important applications for effective disease control (4). Nonetheless, it appears that some reflection is needed on the true nature of these models with respect to human disease, thus enhancing the relevance of the current data extrapolations from animal models and better defining the field of potential applications to humans. In this reflection, we succinctly consider the main factors which influence the success of Candida albicans as a vaginal pathogen, i.e., estrogens, commensalism, and immune-priming-tolerance axis, as well as the biochemical and microbiological properties of the vaginal environment. We also provide some suggestions that may be useful to overcome the shortcomings of the current models so as to improve or even replace them. A detailed review of the vast literature on RVVC and animal models of vaginal candidiasis is outside the scope of this paper, as is a review of studies made in human reconstituted vaginal epithelial cells (VEC). We do not discuss the other forms of mucosal candidiasis (oral and intestinal) which differ so much from VVC/RVVC in relation to risk factors, pathogenicity determinants, and immune responses to infection, although some mentions of them are made where appropriate. For detailed information concerning the areas mentioned above, a number of excellent reviews are available (9–12). This review focuses on the main contributions with respect to the Candida-host relationship in the rodent models of vaginal candidiasis versus clinical disease. A model of experimental vaginal candidiasis in nonhuman primates (two species of macaques) has been reported (13), but no further attempts were made to study the Candida-host relationship in this model (see also below). Here we start with brief historical notes and a description of the main features characterizing the two commonly if not exclusively used vaginal candidiasis models in rats and mice.

SHORT HISTORY OF RODENT MODELS AND THEIR MAIN RESULTS

The rat model.The rat model of vaginal candidiasis has been in use since early 1960, mostly with the purpose of assessing the anticandidal activity of new drugs. A substantial contribution to the physiology of the model and its strong dependence on pseudoestrus maintenance was provided first by Sobel and Muller (14) and then by Kinsman and Collard (15), who showed the chronic nature of the infection and provided details about ovariectomy and the estrogen usage that is required for infection to occur. The burden of infection was assessed by enumeration of CFU in the vaginal fluid or in excised vaginal tissue following an intravaginal Candida challenge. In the experiments conducted by the investigators referred to above, there was no evidence of strong leukocyte infiltration in pseudoestrus animals challenged by the fungus, and there were no appreciable or measurable clinical signs of disease. Candida pathogenicity and host responses at the vaginal level were mostly addressed by Cassone and collaborators, who highlighted the nature of the various host immunoeffectors involved in the acquired protection and showed the critical role played by the secretory aspartyl proteinases (Sap) in this model (7, 16–18). An intense hyphal growth with biofilm adhering to the vaginal epithelial cells (VEC) was the dominant cytological aspect of the infection, with evidence for macrophages rather than neutrophil infiltration (19). A detailed description of the model has been reported elsewhere (20). Among the immunoeffectors shown to provide anticandidal protection in this model, antibodies against a major Sap (Sap2) and surface mannoproteins were prevalent, although a degree of protection could be conferred by adoptive transfer of both B and T cells from Candida-immunized rats to naive animals. Anti-Sap2 antibodies were shown to inhibit adherence and biofilm formation by Candida on the vaginal epithelial surface (7, 19). Together with some clinical data from RVVC subjects (16), these studies supported the notion of anti-Candida vaccination in women affected by RVVC (reviewed in reference 4).

The mouse model.A second and more popular model of vaginal candidiasis is a murine model, particularly that developed and adopted by Fidel and collaborators (21–26). Advantages of this model over the rat one are lower cost, easy handling, and great availability of genetically modified animals. In addition, no ovariectomy is necessary for infection, as estrogen administration alone is sufficient for pseudoestrus induction. As in rats, the infection is evaluated and monitored by determination of colony-forming counts (CFU) of fungal cells in the vaginal fluid or in the tissue of excised vagina following intravaginal Candida administration. Fidel and collaborators showed the typical estrogen dependence of Candida infection, the changes of the surface vaginal epithelium caused by the pseudoestrus, the fungal biofilm on vaginal epithelium, and the partial refractoriness to a subsequent reinfection, as in rats (22–25). Striking differences from the rat model regarding mechanisms of immune responses and inflammation have been reported in most of the studies mentioned above. In mice, the fungal intravaginal challenge causes a strong inflammatory exudate with dominance of polymorphonuclear cells (neutrophils) and the production of neutrophil-chemoattractive chemokines and cytokines by the VEC (25). No signs of induction of adaptive immune responses and protective T cells or antibodies have been reported; rather, a protective state could be attributed only to the absence of inflammatory response (26). Some authors, using a variant mouse model, have reported the induction of Th17 and of a particular subset of CD4 T cells and have associated the production of cytokines interleukin-17A (IL-17A) and IL-22, beta-defensin, and anti-Candida defensive peptides with at least partial control of the infection, with some similarity to oral candidiasis (11, 27, 28). More recently, the activation of a typical Nod-like receptor protein 3 (NLRP3) inflammasome-mediated cytokine response has been reported to occur (29–31), and Sap production by C. albicans has been associated with vaginal inflammation, indicating that one or more of these enzymes could indeed be the direct or indirect cause of inflammasome activation in the epithelial cells (29, 30, 32). Interestingly, the data on the relevant pathogenetic role exerted by those enzymes in the mouse model are probably the only data that largely match those reported in the rat model and in women (see above), hence collectively suggesting that C. albicans Sap could indeed play a dominant pathogenic role in vaginal candidiasis. Data reported by Naglik's research group, using a similar mouse vaginal infection model, also highlighted the role of some Sap enzymes in contributing to infection, which is in keeping with SAP gene expression in infected women (33, 34). Overall, among the many putative virulence factors of C. albicans, including the transition from dimorphic yeast to hypha, some adhesins (in particular, those of the agglutinin-like sequence [ALS] family) (6, 35), and biofilm formation, Sap enzymes have been those most intensely studied and advocated for as having a role in vaginal candidiasis and perhaps also in some forms of oral infection (36).

FACTORS CONDITIONING OR DIFFERENTIALLY MODULATING THE OUTCOME OF INFECTION AND HOST RESPONSE IN RAT AND MOUSE VAGINAL CANDIDIASIS

Estrogens.The most salient, common aspect that generates confidence in the reliability of the models is that rodent models and human infection are stringently estrogen dependent. Vaginal candidiasis is extremely infrequent in prepubertal and, to some extent, in postmenopausal women, and women with a history of infrequent or rare VVC episodes become susceptible following hormone replacement therapy (3). Estrogens exert a multifunctional permissive role for vaginal candidiasis through a number of both host- and Candida-directed effects (reviewed in reference 4). Both rats and mice must be placed under stable pseudoestrus conditions to establish experimental vaginal infection. In rats, this is usually achieved by ovariectomy followed by estrogen treatment, although recent studies showed that a unique regimen of estrogen treatment may be sufficient to allow C. albicans infection to occur (37). Of note, ovariectomy has been shown to cause a reduction in the number of lactobacillus components of the vaginal microbiota (38; see also below). In mice, estrogen administration is the standard treatment, taking into account the differing susceptibilities of different animal strains to estrogens (39, 40). In both rodents, pseudoestrus induces stage-dependent, profound changes in the vaginal epithelium, with a keratinized surface to which fungal cells strongly adhere and upon which they multiply by hyphal growth and by eventually forming a biofilm (19, 24). Besides these structure-modifying properties, other estrogen-induced biological activities appear to be of special relevance for VVC/RVVC. In particular, estradiol has been reported to inhibit the differentiation of Th17 cells, a subset of CD4 cells supposedly involved in the mucosal antifungal defense; the evidence is stronger, however, in oral and intestinal than in vaginal infection (11, 27, 41, 42). Overall, there is evidence that the responses to estrogen have similarities in rodents and humans. However, the marked differences between rodent models and humans in other relevant biological aspects need to be considered, as shown below.

Commensalism and immune priming.C. albicans is a normal, though minor, component of the human microbiota, whereas it is absent from microbiota of rodents. Candida commensalism shapes human anti-Candida immunity by priming/boosting a strong memory immunity as evidenced by both T and B cell recall responses to fungal antigens in normal, healthy subjects, perhaps also involving a persistent activation of innate anti-Candida immunoeffectors (43–45). It is logical to think that the broad-spectrum immunity described above has a role in the resistance of healthy subjects to candidiasis, but how and to what degree this role is played at the vaginal level is unknown. Women with neutropenia or a low level of CD4+ T cells, as in the case of those living with AIDS, who suffer severe systemic or oroesophageal candidiasis, respectively, are not at major risk of vaginal candidiasis in the absence of the known typical risk factors for vaginitis such as pregnancy, diabetes, hormone replacement therapy, and antibiotic therapy, to mention only the major ones (3, 9, 10). Therefore, if commensalism-induced immunity has a functional role in vaginal candidiasis, this must be sought for in the unique immunity of the female reproductive tract rather than in systemic or other nonvaginal mucosal site-derived factors. As outlined elsewhere (4), the vagina is indeed a strongly tolerant body site as it must accept both constantly present (the vaginal microbiota) and occasionally present (semen and fetal) non-self-material. Hence, a delicate balance is maintained that must take into account two equally essential needs for the health of the vagina—immune defense (resistance) and immune tolerance (46). Disease may well occur by loss of tolerance rather than by loss of resistance. Commensalism-shaped immunity is likely to participate in specific mechanisms of C. albicans vaginal immune tolerance through a complex set of immune-regulatory responses. Among them, an experimentally supported concept is that tolerance is regulated by IL-22 and IDO (indoleamine 2,3-dioxygenase)-dependent tryptophan metabolism (kynurenins) (8). Importantly, tolerance can be overwhelmed or bypassed by a high burden of fungal cells, particularly in the hyphal forms, in the presence of the aforementioned typical factors predisposing subjects to candidal vaginitis. On this basis, a reasonable assumption is that in women with RVVC, the tolerance “threshold” is lower and is more easily surpassed than in women not prone to VVC, possibly because of various disease-predisposing gene polymorphisms or other unknown factors (47). A demonstration that the commensalism-immune priming-tolerance axis of the human vagina can be overwhelmed by high burdens of C. albicans cells was provided by studies performed by Fidel's research group in human volunteers (48; see below for further consideration of these studies).

On the other hand, the role of commensalism in vaginal candidiasis is clearly appreciated when the source of infection is considered. There is sufficient evidence to suggest that most of the cases of VVC/RVVC are of an endogenous nature, due to vaginal colonization from the intestine or the cervico-vaginal-vulvar areas or skin or even the persistence of a low number of fungal cells in the vagina (endogenous infection in Candida—primed) (3). This makes an important, perhaps critical, difference from experimental rodent models in which the infection is achieved by direct intravaginal inoculation of high burdens of fungal cells, no signs of infection other than the fungus burden are clinically appreciable, and the animals are immunologically naive to the fungus (exogenous infection in Candida—unprimed). While not impossible, it is unlikely that endogenous infection occurs through the introduction of a single bout of fungal cells (in some studies, millions) from the intestine/perivaginal area. Exogenous infection in animals without any preexisting immunity to Candida can be naturally “proinflammatory,” particularly under neutral pH conditions and in the absence of lactobacilli (as in mice), all conditions which favor rapid and extensive hyphal development. Recent data suggest that lactate, an abundant product of sugar fermentation in a lactobacillus-dominated vaginal environment, downmodulates proinflammatory cytokine production (49). From this point of view, the mouse model would appear to be the more “proinflammatory” model and, in fact, rapid and sustained intravaginal influx of neutrophils accompanied by high levels of inflammasome-dependent IL-1β is typical of this model (29–31). A similar polymorphonuclear leukocyte (PMN) influx is not seen in the rat model, which, under conditions of estrogen treatment, may have an acidic rather than neutral vaginal pH and hyphae that are formed more slowly. Moreover, lactobacilli are present and can play an anti-inflammatory role (50, 51). Only limited macrophage infiltration is seen in these Candida-infected animals, cell-mediated, Th1-type responses to C. albicans are present, and both proinflammatory and anti-inflammatory cytokines are produced during the course of infection (17, 18, 52). This picture is somewhat closer to that of human infection, particularly in the Th1-type response (53), provided that there is no concomitant bacterial infection.

Despite all the findings described above, strong support for the concept that mouse rather than rat models could be a proxy of vaginal candidiasis in women was derived from the already-mentioned studies by Fidel's research group (47) in human volunteers intravaginally challenged with live fungal cells (exogenous infection). In those studies, a correlation was found between fungal intravaginal burden and inflammation, as shown by leukocyte infiltration and induction of a proinflammatory cytokine-rich environment. However, the caveat remains that a direct intravaginal challenge with high fungal loads would not reflect the natural source of infection or the immune responses that follow a naturally acquired infection, particularly in RVVC subjects. In the above-reported exogenous infection, there was no influence of the stage of the menstrual cycle, whereas it is well known that in naturally infected women, VVC essentially occurs or worsens in the luteal phase of the cycle, when estrogen and progesterone levels rise (3). Importantly, and in contrast to rodent models, no keratinization of vaginal epithelial surface has ever been reported in women (3).

The vaginal microbiota and pH issues.It is generally assumed that the vaginal microbiota exerts a role in the vaginal healthy state and protects against Candida infection, although it is unknown to what extent and by which mechanisms this occurs. In healthy premenopausal women, this role is dominantly played by several Lactobacillus spp. which produce lactic acid from sugar substrates and so render the vaginal microenvironment typically acidic (54). In a recent study (55), the vaginal microbiota of mice was seen to be mostly composed of Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, and Cyanobacteria, with no evidence of dominant lactobacilli. In contrast, Lactobacillus spp. have been reported to be a major component of rat vaginal microflora and can contribute to make the vaginal pH lower than neutral under estrus conditions, although not as uniformly as in humans (56–58). Ovariectomized rats lost the lactobacillus component of the vaginal microbiota but regained its full composition, and its acidic condition, as a consequence of estrogen treatment (38). Using an ex vivo model of the cervicovaginal epithelium, Abramov and collaborators (50) have recently shown that Lactobacillus crispatus, a major component of the vaginal microbiota, binds to epithelial cells and induces NF-κB activation but does not induce expression of innate immunity mediators and proinflammatory cytokines such as IL-8, IL-1β, IL-1α, and tumor necrosis factor alpha (TNF-α). L. crispatus 2029 inhibited IL-8 production in epithelial cells and increased production of IL-6 working as anti-inflammatory cytokine, hence maintaining the homeostasis of female reproductive tract.

Overall, the studies performed so far highlight important differences between rats and mice treated with estrogens with regard to the pH of both the vaginal microenvironment and the vaginal microbiota and overall immune responses. However, rats appear to be less distant than mice from women in some of those vaginal parameters. In particular, it is difficult to conceive that similar immune-pathogenetic mechanisms are taking place at such different pH values as 4.5 and 7. Nonetheless, we should recognize that the “real” pH of the vaginal microniches where infectious foci develop and immunoeffectors are recruited is not known and could be quite different and dynamically variable from the “static” one measured in the vaginal fluid.

Table 1 presents a short summary of the main similarities and differences between rat and mouse models, as well as between rodent models and human candidiasis.

View this table:
  • View inline
  • View popup
TABLE 1

Major factors determining and/or regulating human, rat, and mouse vaginal candidiasis

CONCLUSIONS ABOUT THE RELEVANCE OF RODENT MODELS TO HUMAN DISEASE AND SUGGESTIONS FOR FUTURE WORK

The data and considerations summarized above point out that experimental vaginal candidiasis in rats and, to a greater extent, in mice should be taken cautiously as a proxy of human VVC. This conclusion particularly applies to women with RVVC who express unique immunopathogenetic and vulnerability aspects. This specifically refers to the immune regulation along the axis of commensalism-immunity-tolerance that is present in women and naturally absent and not reproduced in rodent models. This does not mean that the pathogenicity and immunological studies done with these models are irrelevant to human candidiasis. There are indeed factors in rodent models that are quite relevant to the control of human infection. These include the expression of some fungus virulence traits (dimorphic transition, biofilm formation, some adhesins, and Sap, to mention the major ones) and the capacity of mounting a protective immune response under conditions of estrogenic stimulation with demonstrated or probable equivalence in human infection. Nonetheless, the data also point out the existence of major differences and gaps of relevant information that need to be filled in order to enhance the proximity and relevance of animal models to disease in women.

A point that usually escapes attention is that vaginitis is also defined in women by signs and symptoms such as vulvar erythema, edema, itching, vaginal discharge, and painful sexual intercourse. They can be quantified in women and are absent or not measurable in animals. When signs and symptoms of vaginal candidiasis are present, the mere presence of Candida cells, not their intravaginal burden, is a clinical, diagnostic parameter of infection in women, whereas fungus burden is the endpoint metric of animal models. It should be recognized that microbial burden and cytokine detection cannot be taken as equivalent to symptoms and tissue inflammation.

In our opinion, the primary challenge to meet is the design of vaginal infection studies in animals colonized by C. albicans, thus expressing a primed immunity to this opportunistic pathogen. The ideal one would be a model in nonhuman primates that are Candida colonized and hence immune primed. An attempt at using macaques was made by Fidel's research group (9) but without a substantial follow-up. Interestingly, a successful infection in rhesus macaques was not paralleled by disease signs (9). Investigations of vaginal candidiasis in nonhuman primate models are cost- and labor-intensive and are not easily approved by institutional boards. In mice, a pioneering study was conducted by Cutler's research group showing that animals fed with antibiotic-containing water were stably colonized by the fungus (60). Other studies have largely confirmed and expanded on the mechanisms of Candida colonization in these mice, with no data reported, however, on vaginal colonization and infection (59, 61–63). Since antibiotic treatment is a well-known risk factor for vaginal candidiasis in women, this model should be characterized by some level of spontaneous susceptibility to vaginal candidiasis. This also applies to the rat model if it could be demonstrated that antibiotic treatment induces persistent and stable vaginal colonization.

Nonetheless, the search for other laboratory animals that are naturally and stably colonized without antibiotics would be desirable. Besides nonhuman primates, a more laboratory-suitable small animal recently reported to be colonized by the fungus without antibiotic treatment is the piglet, which, importantly, has an intestinal microbiota not dissimilar from the human one (64). No data have been published about the possibility of achieving candidal vaginitis in these animals. Other possibilities to explore include the use of germfree mice, despite the peculiar conditions imposed by the use of these animals.

A second issue quite appropriate to address in rodent models is the study of the nature and mechanisms of protection acquired after resolution of the primary vaginal infection by C. albicans. In both rats and mice, healing of the primary infection generates a state of partial refractoriness (resistance) to a second fungal challenge (5, 23). This is an important similarity between the two models and has implications for disease epidemiology and vaccination in women. For instance, why is it that, among the many women (70% to 80%) who suffer infrequent Candida vaginitis episodes, only a fraction (5% to 8%) develop RVVC? Is postinfection acquired resistance also present in women, and, if so, what mechanisms are involved? In rats, refractoriness and protection are highly specific, requiring functional T cells and memory compartments, and can be transferred by immune cells and antibodies; thus, it is considered a specific postinfection acquired immunity, a sort of natural vaccination. No such adaptive response appears to be present in mice, although some short-term protective “memory” triggered by activation of local or intravaginally recruited innate immune effectors such as the macrophages is theoretically possible (44, 45). All this suggests a priming of anti-Candida immunity caused by the experimental infection. It would be important to know whether this process mimics the natural priming induced by the commensalism and its differences. These studies may reveal important, critical information for the progress of anti-Candida vaccination and immunotherapy studies.

The third and perhaps the most important aspect is encouraging and stimulating research programs with close collaborations between experimental microbiologists and clinicians or clinical investigators. There are relatively few data on Candida pathogenicity and anti-Candida immune responses obtained by direct sampling of the vaginal cavity and tissues of Candida-infected women. When feasible, materials from vaginal or cervicovaginal tissues may provide direct information to compare with the relevant findings from animal studies. Improved studies performed with ex vivo tissues (such as, for instance, those taken from routine hysterectomies) can usefully add to the reconstituted vaginal cell lines already used (65). Overall, the aforementioned expansion of our model studies could favor a more comprehensive understanding of the mechanisms controlling vaginal candidiasis and could provide important insight into the relationship between the widely used rodent models and human disease.

ACKNOWLEDGMENT

We thank Anna Maria Marella for secretarial help in the preparation of the manuscript.

  • Copyright © 2016, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Foxman B,
    2. Muraglia R,
    3. Dietz JP,
    4. Sobel JD,
    5. Wagner JJ
    . 2013. Prevalence recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 17:340–345. doi:10.1097/LGT.0b013e318273e8cf.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ringdahl EN
    . 2006. Recurrent vulvovaginal candidiasis. Mo Med 103:165–168.
    OpenUrlPubMed
  3. 3.↵
    1. Sobel JD
    . 9 July 2015. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol doi:10.1016/j.ajog.2015.06.067.
    OpenUrlCrossRef
  4. 4.↵
    1. Cassone A
    . 2015. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG 122:785–794. doi:10.1111/1471-0528.12994.
    OpenUrlCrossRef
  5. 5.↵
    1. Cassone A,
    2. Boccanera M,
    3. Adriani D,
    4. Santoni G,
    5. De Bernardis F
    . 1995. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 63:2619–2624.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Ibrahim AS,
    2. Luo G,
    3. Gebremarian T,
    4. Lee H,
    5. Schmidt CS,
    6. Hennesey JP,
    7. French SW,
    8. Filler SG,
    9. Edwards JE
    . 2013. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine 31:5549–5556. doi:10.1016/j.vaccine.2013.09.016.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. De Bernardis F,
    2. Amacker M,
    3. Arancia S,
    4. Sandini S,
    5. Gremion C,
    6. Zurbriggen R,
    7. Moser C,
    8. Cassone A
    . 2012. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 30:4490–4497. doi:10.1016/j.vaccine.2012.04.069.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. De Luca Carvalho AA,
    2. Cunha C,
    3. Iannitti RG,
    4. Pitzurra L,
    5. Giovannini G,
    6. Mencacci A,
    7. Bartolomei L,
    8. Moretti S,
    9. Massi-Benedetti C,
    10. Fuchs D,
    11. De Bernardis F,
    12. Puccetti PP,
    13. Romani L
    . 2013. IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. PLoS Pathog 9:e1003486. doi:10.1371/journal.ppat.1003486.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Naglik JR,
    2. Fidel PL, Jr,
    3. Odds F
    . 2008. Animal models of mucosal Candida infection. FEMS Microbiol Lett 283:129–139. doi:10.1111/j.1574-6968.2008.01160.x.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Fidel PL, Jr
    . 1999. Host defense against oropharyngeal and vaginal candidiasis: site-specific differences. Rev Iberoam Micol 16:8–15.
    OpenUrlPubMed
  11. 11.↵
    1. Hernández-Santos N,
    2. Gaffen SL
    . 2012. Th17 cells in immunity to Candida albicans. Cell Host Microbe 11:425–435. doi:10.1016/j.chom.2012.04.008.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Schaller M,
    2. Weindl G
    . 2009. Models of oral and vaginal candidiasis based on in vitro reconstituted human epithelia for the study of host-pathogen interactions. Methods Mol Biol 470:327–345. doi:10.1007/978-1-59745-204-5_23.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Steele C,
    2. Ratterree M,
    3. Fidel PL, Jr
    . 1999. Differential susceptibility of two species of macaques to experimental vaginal candidiasis. J Infect Dis 180:802–810. doi:10.1086/314964.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Sobel JD,
    2. Muller G
    . 1983. Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis. Antimicrob Agents Chemother 24:434–436. doi:10.1128/AAC.24.3.434.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Kinsman M,
    2. Collard AE
    . 1986. Hormonal factors in vaginal candidiasis in rats. Infect Immun 53:498–504.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Cassone A,
    2. De Bernardis F,
    3. Mondello F,
    4. Ceddia T,
    5. Agatensi L
    . 1987. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 156:777–783. doi:10.1093/infdis/156.5.777.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. de Bernardis F,
    2. Santoni G,
    3. Boccanera M,
    4. Spreghini E,
    5. Adriani D,
    6. Morelli L,
    7. Cassone A
    . 2000. Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun 68:3297–3304. doi:10.1128/IAI.68.6.3297-3304.2000.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Santoni G,
    2. Boccanera M,
    3. Adriani D,
    4. Lucciarini R,
    5. Amantini C,
    6. Morrone S,
    7. Cassone A,
    8. De Bernardis F
    . 2002. Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4 (+) T cells and possible participation of other local lymphocyte effectors. Infect Immun 70:4791–4797. doi:10.1128/IAI.70.9.4791-4797.2002.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. De Bernardis F,
    2. Liu H,
    3. O'Mahony R,
    4. La Valle R,
    5. Bartollino S,
    6. Sandini S,
    7. Grant S,
    8. Brewis N,
    9. Tomlinson I,
    10. Basset RC,
    11. Holton J,
    12. Roitt IM,
    13. Cassone A
    . 2007. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 195:149–157. doi:10.1086/509891.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. De Bernardis F,
    2. Lorenzini R,
    3. Cassone A
    . 1999. Rat model of Candida vaginal infection, p 735–740. In Zak O, Sande MA (ed), Handbook of animal models of infection. Elsevier, Philadelphia, PA.
  21. 21.↵
    1. Fidel PL, Jr
    . 2007. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 57:2–12. doi:10.1111/j.1600-0897.2006.00450.x.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Fidel PL, Jr,
    2. Cutright J,
    3. Steele C
    . 2000. Effect of reproductive hormones on experimental vaginal candidiasis. Infect Immun 68:651–657. doi:10.1128/IAI.68.2.651-657.2000.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Fidel PL, Jr,
    2. Lynch ME,
    3. Conaway DH,
    4. Tait L,
    5. Sobel JD
    . 1995. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun 63:547–553.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Harriott MM,
    2. Lilly EA,
    3. Rodriguez TE,
    4. Fidel PL, Jr,
    5. Noverr MC
    . 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156:3635–3644. doi:10.1099/mic.0.039354-0.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Yano J,
    2. Lilly E,
    3. Barousse M,
    4. Fidel PL, Jr
    . 2010. Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis. Infect Immun 78:5126–5137. doi:10.1128/IAI.00388-10.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Peters BM,
    2. Yano J,
    3. Noverr MC,
    4. Fidel PL, Jr
    . 2014. Candida vaginitis: when opportunism knocks, the host responds. PLoS Pathog 10:e1003965. doi:10.1371/journal.ppat.1003965.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Pietrella D,
    2. Rachini A,
    3. Pines M,
    4. Pandey N,
    5. Mosci P,
    6. Bistoni F,
    7. d'Enfert C,
    8. Vecchiarelli A
    . 2011. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One 6:e22770. doi:10.1371/journal.pone.0022770.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Pietrella D,
    2. Pandey N,
    3. Gabrielli E,
    4. Pericolini E,
    5. Perito S,
    6. Kasper L,
    7. Bistoni F,
    8. Cassone A,
    9. Hube B,
    10. Vecchiarelli A
    . 2013. Secreted aspartic proteases of Candida albicans activate the NLRP3 inflammasome. Eur J Immunol 43:679–692. doi:10.1002/eji.201242691.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Bruno VM,
    2. Shetty AC,
    3. Yano J,
    4. Fidel PL, Jr,
    5. Noverr MC,
    6. Peters BM
    . 2015. Transcriptomic analysis of vulvovaginal candidiasis identifies a role for the NLRP3 inflammasome. mBio 6 (2):pii: 00182-15. doi:10.1128/mBio.00182-15.
    OpenUrlCrossRef
  30. 30.↵
    1. Pericolini E,
    2. Gabrielli E,
    3. Amacker M,
    4. Kasper L,
    5. Roselletti E,
    6. Luciano E,
    7. Sabbatini S,
    8. Kaeser M,
    9. Moser C,
    10. Hube B,
    11. Vecchiarelli A,
    12. Cassone A
    . 2015. Secretory aspartyl proteinases cause vaginitis and can mediate vaginitis caused by Candida albicans in mice. mBio 6:e00724. doi:10.1129/mBio.00724-15.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Borghi M,
    2. AdeLuca Puccetti M,
    3. Jaeger M,
    4. Mencacci A,
    5. Oikonomou V,
    6. Parian M,
    7. Garlanda C,
    8. Moretti S,
    9. Bartoli A,
    10. Sobel J,
    11. van de Veerdonk FL,
    12. Dinarello CA,
    13. Netea MG,
    14. Romani L
    . 2015. Pathogenic NLRP3 inflammasome activity during Candida infection is negatively regulated by IL-22 via activation of NLRC4 and IL-1Ra. Cell Host Microbe 18:198–209. doi:10.1016/j.chom.2015.07.004.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Kozik A,
    2. Gogol M,
    3. Bochenska O,
    4. Karlowska-Kuleta J,
    5. Wolak N,
    6. Kamysz W,
    7. Aoki W,
    8. Ueda M,
    9. Faussner A,
    10. Rapala-Kozik M
    . 2015. Kinin release from human kininogen by 10 aspartic proteases produced by pathogenic yeast Candida albicans. BMC Microbiol 15:60–74. doi:10.1186/s12866-015-0394-8.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Naglik JR,
    2. Moyes D,
    3. Makwana J,
    4. Kanzaria P,
    5. Tsichlaki E,
    6. Weindl G,
    7. Tappuni AR,
    8. Rodgers CA,
    9. Woodman AJ,
    10. Challacombe SJ,
    11. Schaller M,
    12. Hube B
    . 2008. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 154:3266–3280. doi:10.1099/mic.0.2008/022293-0.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Naglik JR,
    2. Rodgers CA,
    3. Shirlaw PJ,
    4. Dobbie JI,
    5. Fernandes-Naglik LL,
    6. Greenspan D,
    7. Agabian N,
    8. Challacombe SJ
    . 2003. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 188:469–479. doi:10.1086/376536.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Hoyer LL,
    2. Green CB,
    3. Oh SH,
    4. Zhao X
    . 2008. Discovering the secrets of the Candida albicans agglutinin-like sequence (ALS) gene family—a sticky pursuit. Med Mycol 46:1–15. doi:10.1080/13693780701435317.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Kumar R,
    2. Saraswat D,
    3. Tati S,
    4. Edgerton M
    . 2015. Novel aggregation properties of Candida albicans secreted aspartyl proteinase Sap6 mediate virulence in oral candidiasis. Infect Immun 83:2614–2626. doi:10.1128/IAI.00282-15.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Carrara MA,
    2. Donatti L,
    3. Damke E,
    4. Svidizinski TI,
    5. Consolaro ME,
    6. Batista MR
    . 2010. A new model of vaginal infection by Candida albicans in rats. Mycopathologia 170:331–338. doi:10.1007/s11046-010-9326-1.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Bezirtzoglou E,
    2. Voidarou CH,
    3. Papadaki AP,
    4. Tiuotsias A,
    5. Kotsovolou O,
    6. Konstandi O
    . 2008. Hormone therapy alters the composition of the vaginal microflora in ovariectomized rats. Microb Ecol 55:751–759. doi:10.1007/s00248-007-9317-z.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Clemons KV,
    2. Spearow JL,
    3. Parmar R,
    4. Espiritu M,
    5. Stevens DA
    . 2004. Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun 72:4878–4880. doi:10.1128/IAI.72.8.4878-4880.2004.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Mosci P,
    2. Pietrella D,
    3. Ricci G,
    4. Pandey N,
    5. Monari C,
    6. EPericolini Gabrielli E,
    7. Perito S,
    8. Bistoni F,
    9. Vecchiarelli A
    . 2013. Mouse strain-dependent differences in estrogen sensitivity during vaginal candidiasis. Mycopathologia 175:1–11. doi:10.1007/s11046-012-9589-9.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Lasarte S,
    2. Elsner D,
    3. Guía-González M,
    4. Ramos-Medina R,
    5. Sánchez-Ramón S,
    6. Esponda P,
    7. Muñoz-Fernández MA,
    8. Relloso M
    . 2013. Female sex hormones regulate the Th17 immune response to sperm and Candida albicans. Hum Reprod 28:3283–3291. doi:10.1093/humrep/det348.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Chen RY,
    2. Fan YM,
    3. Zhang Q,
    4. Liu S,
    5. Li Q,
    6. Ke GL,
    7. Li C,
    8. You Z
    . 2015. Estradiol inhibits Th17 cell differentiation through inhibition of RORγT transcription by recruiting the ERα/REA complex to estrogen response elements of the RORγT promoter. J Immunol 194:4019–4028. doi:10.4049/jimmunol.1400806.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Ausiello CM,
    2. Spagnoli GC,
    3. Boccanera M,
    4. Casalinuovo I,
    5. Malavasi F,
    6. Casciani CU,
    7. Cassone A
    . 1986. Proliferation of human peripheral blood mononuclear cells induced by Candida albicans and its cell wall fractions. J Med Microbiol 22:195–202. doi:10.1099/00222615-22-3-195.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Bistoni F,
    2. Vecchiarelli A,
    3. Cenci E,
    4. Puccetti P,
    5. Marconi P,
    6. Cassone AA
    . 1986. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 51:668–674.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Netea MG,
    2. Quintin J,
    3. van der Meer JW
    . 2011. Trained immunity: a memory for innate host defense. Cell Host Microbe 9:355–361. doi:10.1016/j.chom.2011.04.006.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Sansonetti PJ
    . 2011. To be or not to be a pathogen: that is the mucosally relevant question. Mucosal Immunol 4:8–14. doi:10.1038/mi.2010.77.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Smeekens SP,
    2. van de Veerdonk FL,
    3. Kullberg BJ,
    4. Netea MG
    . 2013. Genetic susceptibility to Candida infections. EMBO Mol Med 5:805–813. doi:10.1002/emmm.201201678.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Fidel PL, Jr,
    2. Barousse M,
    3. Espinosa T,
    4. Ficarra M,
    5. Sturtevant J,
    6. Martin DH,
    7. Quayle AJ,
    8. Dunlap KK
    . 2004. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 72:2939–2946. doi:10.1128/IAI.72.5.2939-2946.2004.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Ene IV,
    2. Cheng SC,
    3. Netea MG,
    4. Brown AJ
    . 2013. Growth of Candida albicans cells on the physiologically relevant carbon source lactate affects their recognition and phagocytosis by immune cells. Infect Immun 81:238–248. doi:10.1128/IAI.01092-12.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Abramov V,
    2. Khlebnikov VV,
    3. Kosarev I,
    4. Bairamova G,
    5. Vasilenko R,
    6. Suzina N,
    7. Machulin A,
    8. Sakulin V,
    9. Kulikova N,
    10. Vasilenko N,
    11. Karlyshev A,
    12. Uversky V,
    13. Chikindas ML
    . 2014. Probiotic properties of Lactobacillus crispatus 2,029: homeostatic interaction with cervicovaginal epithelial cells and antagonistic activity to genitourinary pathogens. Probiotics Antimicrob Proteins 6:165–176. doi:10.1007/s12602-014-9164-4.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Iraporda C,
    2. Errea AA,
    3. Romanin DE,
    4. Cayet D,
    5. Pereyra E,
    6. Pignataro O,
    7. Sirard JC,
    8. Garrote GL,
    9. Abraham AG,
    10. Rumbo M
    . 2015. Lactate and short chain fatty acids produced by microbial fermentation downregulate proinflammatory responses in intestinal epithelial cells and myeloid cells. Immunobiology 220:1161–1169. doi:10.1016/j.imbio.2015.06.004.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Ji HX,
    2. Zou YL,
    3. Duan JJ,
    4. Jia ZR,
    5. Li XJ,
    6. Wang Z,
    7. Li L,
    8. Li YW,
    9. Liu GY,
    10. Tong MQ,
    11. Li XY,
    12. Zhang GH,
    13. Dai XR,
    14. He L,
    15. Li ZY,
    16. Cao C,
    17. Yang Y
    . 2013. The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization. PLoS One 8:e56004. doi:10.1371/journal.pone.0056004.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Piccinni MP,
    2. Vultaggio A,
    3. Scaletti C,
    4. Livi C,
    5. Gomez MJ,
    6. Giudizi MG,
    7. Biagiotti R,
    8. Cassone A,
    9. Romagnani S,
    10. Maggi E
    . 2002. Type 1 T helper cells specific for Candida albicans antigens in peripheral blood and vaginal mucosa of women with recurrent vaginal candidiasis. J Infect Dis 186:87–93. doi:10.1086/341129.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Petrova MI,
    2. Lievens E,
    3. Malik S,
    4. Imholz N,
    5. Lebeer S
    . 2015. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol 6:81. doi:10.3389/fphys.2015.00081.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Barfod KK,
    2. Roggenbuck MM,
    3. Hansen LH,
    4. Schjørring S,
    5. Larsen ST,
    6. Sørensen SJ,
    7. Krogfelt KA
    . 2013. The murine lung microbiome in relation to the intestinal and vaginal bacterial communities. BMC Microbiol 13:303–311. doi:10.1186/1471-2180-13-303.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Larsen B,
    2. Markovetz AJ,
    3. Galask RP
    . 1976. The bacterial flora of the female rat genital tract. Proc Soc Exp Biol Med 151:571–574. doi:10.3181/00379727-151-39261.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Eisa EA
    . 1950. The formation of lactic acid in the vagina of adult rat. Acta Endocrinol 4:285–290.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Baker HJ,
    2. Russell Lindsey JR,
    3. Weisbroth SH
    (ed). 1976. The laboratory rat: biology and diseases, vol 1. Academic Press, New York, NY.
  59. 59.↵
    1. Koh AY
    . 2013. Murine models of Candida gastrointestinal colonization and dissemination. Eukaryot Cell 12:1416–1422. doi:10.1128/EC.00196-13.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Cutler JE,
    2. Corti M,
    3. Lambert P,
    4. Ferris M,
    5. Xin H
    . 2011. Horizontal transmission of Candida albicans and evidence of a vaccine response in mice colonized with the fungus. PLoS One 6:e22030. doi:10.1371/journal.pone.0022030.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Vautier S,
    2. Drummond RA,
    3. Chen K,
    4. Murray GI,
    5. Kadosh D,
    6. Brown AJP,
    7. Gow NA,
    8. MacCallum DM,
    9. Kolls JK,
    10. Brown G
    . 2015. Candida albicans colonization and dissemination from the murine gastrointestinal tract: the influence of morphology and Th17 immunity. Cell Microbiol 17:445–450. doi:10.1111/cmi.12388.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Fan D,
    2. Coughlin LA,
    3. Neubauer MM,
    4. Kim J,
    5. Kim MS,
    6. Zhan X,
    7. Simms-Waldrip TR,
    8. Xie Y,
    9. Hooper LV,
    10. Koh AY
    . 8 June 2015. Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med doi:10.1038/nm.3871.
    OpenUrlCrossRef
  63. 63.↵
    1. Pande K,
    2. Chen C,
    3. Noble SM
    . 2013. Passage through the mammalian gut triggers a phenotypic switch that promotes Candida albicans commensalism. Nat Genet 45:1088–1091. doi:10.1038/ng.2710.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Hoeflinger JL,
    2. Coleman DA,
    3. Oh SH,
    4. Miller MJ,
    5. Hoyer LL
    . 2014. A piglet model for studying Candida albicans colonization of the human oro-gastrointestinal tract. FEMS Microbiol Lett 357:10–15. doi:10.1111/1574-6968.12500.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Schaller M,
    2. Zakikhani K,
    3. Naglik JR,
    4. Weindl G,
    5. Hube B
    . 2006. Models of oral and vaginal candidiasis based on in vitro reconstituted human epithelia. Nat Protoc 1:2767–2773. doi:10.1038/nprot.2006.474.
    OpenUrlCrossRefPubMedWeb of Science

Author Bios

Figure1

Antonio Cassone (Fellow of the American Academy of Microbiology; former Professor of Microbiology at the Universities of Rome and Perugia, Italy; Visiting Professor at the Imperial College, London, United Kingdom) has major research interests in public health microbiology with a focus on the host-Candida relationship and vaccine immunology. He has published over 300 peer-reviewed papers as primary research publications and filed six patents on vaccines and immune therapeutics. Research and academic careers have been complemented by intense public health service as Research Director and Head of the Department of Infectious Diseases at the ISS (Italian National Health Institute, Rome, 1980 to 2009) and public health consultant for national and international health institutes, including the Health Protection Agency in the United Kingdom and the European Center for Disease Control (Stockholm, Sweden). He received the Gold Medal Award from the Italian Ministry of Health for excellent service in research and actions to fight human infections.

PreviousNext
Back to top
Download PDF
Citation Tools
Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis
Antonio Cassone, Jack D. Sobel
Infection and Immunity Apr 2016, 84 (5) 1255-1261; DOI: 10.1128/IAI.01544-15

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis
Antonio Cassone, Jack D. Sobel
Infection and Immunity Apr 2016, 84 (5) 1255-1261; DOI: 10.1128/IAI.01544-15
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • SHORT HISTORY OF RODENT MODELS AND THEIR MAIN RESULTS
    • FACTORS CONDITIONING OR DIFFERENTIALLY MODULATING THE OUTCOME OF INFECTION AND HOST RESPONSE IN RAT AND MOUSE VAGINAL CANDIDIASIS
    • CONCLUSIONS ABOUT THE RELEVANCE OF RODENT MODELS TO HUMAN DISEASE AND SUGGESTIONS FOR FUTURE WORK
    • ACKNOWLEDGMENT
    • REFERENCES
    • Author Bios
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522